Gilead Sciences: Here’s What Investors Need to Know Before Earnings

Gilead Sciences (NASDAQ:GILD) will report earnings after markets close on Thursday, July 25th. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

Here is your Cheat Sheet to Gilead Sciences Earnings:

Earnings Expectations: Analysts expect earnings of $0.50 per share on revenues of $2.66 billion. Currently, the company’s P/E ratio stands at 32.60.

Analyst Trends:

Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $0.49 and has not changed. For the current year, the average estimate is a profit of $1.98, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Gilead Sciences has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 5,336 7,011 7,949 8,385 9,703
Diluted EPS ($) 1.05 1.41 1.66 1.77 1.64

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012 Mar. 31, 2013
Revenue ($) in millions 2,405.19 2,426.60 2,588.28 2,531.64
Diluted EPS ($) 0.46 0.43 0.47 0.43

Past Performance:
Gilead Sciences has beat analyst estimates 3 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]